Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31715630 | 0.91 | KDM4E (0.38) | ALDH1A1KDM4EESR1CYP3A4CYP2C9 | |
| SCHEMBL13224655 | 0.84 | — | — | |
| SCHEMBL283856 | 0.84 | — | — | |
| SCHEMBL4499212 | 0.79 | KDM4E (0.41) | ALDH1A1KDM4ESMN1; SMN2ESR2 | |
| SCHEMBL17669489 | 0.74 | KDM4E (0.40) | ALDH1A1KDM4E | |
| SCHEMBL1564721 | 0.74 | ESR1 (0.32) | ESR1CYP3A4CYP2C9ESR2APLNR | |
| SCHEMBL4875595 | 0.72 | NCF1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL16179859 | 0.72 | KDM4E (0.39) | ALDH1A1KDM4E | |
| SCHEMBL3509974 | 0.72 | KDM4E (0.39) | ALDH1A1KDM4E | |
| SCHEMBL8069745 | 0.72 | ALDH1A1 (0.39) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070282-A | Pyrazole-1-carboxamides as RIP1 kinase inhibitors | 比西切姆有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119731179-A | IKZF2 degradation agent and application thereof | 密歇根大学董事会 | 2025-03-28 | — | — | CN | disclosed |
| WO-2025037940-A1 | PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS | BISICHEM CO., LTD. (KR) | 2025-02-20 | — | — | WO | disclosed |
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4499649-A1 | IKZF2 DEGRADERS AND USES THEREOF | Regents of the University of Michigan (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-20080207598-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | US | disclosed |
| WO-2008101995-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | WO | disclosed |
| EP-1919471-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2008-05-14 | — | — | EP | disclosed |
| EP-1904068-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABIOID RECEPTOR AGONIST AND OPIOD RECEPTOR AGONIST) | N.V. Organon (NL) | 2008-04-02 | — | — | EP | disclosed |
| EP-1887000-A1 | ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON | Shionogi Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| WO-2007023143-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. ORGANON (NL) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007006732-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABIOID RECEPTOR AGONIST AND OPIOD RECEPTOR AGONIST) | N.V. ORGANON (NL) | 2007-01-18 | — | — | WO | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082931-A1 | Indole derivatives | IDO1, TPH1, IDO2 | ALDH1A1 198/4885KDM4E 1845/4885SMN1; SMN2 1946/4885 |
| US-20080207598-A1 | INDOLE DERIVATIVES | CNR1, CNR2, OPRD1 | ALDH1A1 4175/4885KDM4E 1750/4885SMN1; SMN2 872/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | ALDH1A1 2200/4885KDM4E 3825/4885SMN1; SMN2 3483/4885 |
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | ALDH1A1 2346/4885KDM4E 304/4885SMN1; SMN2 2807/4885 |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | ALDH1A1 1986/4885KDM4E 2192/4885SMN1; SMN2 4586/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 133/4885KDM4E 1773/4885SMN1; SMN2 4744/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 161/4885KDM4E 2141/4885SMN1; SMN2 4599/4885 |
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4652/4885KDM4E 578/4885SMN1; SMN2 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.